Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 2
2013 4
2014 4
2015 6
2016 3
2017 3
2018 3
2019 2
2020 4
2021 11
2022 12
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Pleural Mesothelioma: Treatable Traits of a Heterogeneous Disease.
Bertuccio FR, Agustoni F, Galli G, Bortolotto C, Saddi J, Baietto G, Baio N, Montini S, Putignano P, D'Ambrosio G, Corsico AG, Pedrazzoli P, Stella GM. Bertuccio FR, et al. Among authors: agustoni f. Cancers (Basel). 2023 Dec 6;15(24):5731. doi: 10.3390/cancers15245731. Cancers (Basel). 2023. PMID: 38136277 Free PMC article. Review.
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, Scotti V, Proto C, Bennati C, Di Pietro Paolo M, Platania A, Olmetto E, Agustoni F, Teodorani N, Agbaje V, Russo A. Catania C, et al. Among authors: agustoni f. Crit Rev Oncol Hematol. 2023 Oct;190:104108. doi: 10.1016/j.critrevonc.2023.104108. Epub 2023 Aug 24. Crit Rev Oncol Hematol. 2023. PMID: 37633350 Review.
Radiomics features as predictive and prognostic biomarkers in NSCLC.
Bortolotto C, Lancia A, Stelitano C, Montesano M, Merizzoli E, Agustoni F, Stella G, Preda L, Filippi AR. Bortolotto C, et al. Among authors: agustoni f. Expert Rev Anticancer Ther. 2021 Mar;21(3):257-266. doi: 10.1080/14737140.2021.1852935. Epub 2020 Dec 4. Expert Rev Anticancer Ther. 2021. PMID: 33216651 Review.
Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC).
Cavalieri S, Vitolo V, Barcellini A, Ronchi S, Facoetti A, Campo C, Klersy C, Molinelli S, Agustoni F, Ferretti VV, Silvestri A, Platania M, Del Vecchio M, Durante M, Helm A, Fournier C, Braud F, Pedrazzoli P, Orlandi E, Licitra L. Cavalieri S, et al. Among authors: agustoni f. Future Oncol. 2023 Jan;19(3):193-203. doi: 10.2217/fon-2022-0503. Epub 2023 Mar 28. Future Oncol. 2023. PMID: 36974574 Free article.
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era.
Catania C, Piperno G, Russo A, Greco C, Agustoni F, Scotti V, Proto C, Sangalli C, Patani F, Santacaterina A, Di Pietro Paolo M, Agresti B, Filippi AR, Ramella S. Catania C, et al. Among authors: agustoni f. Crit Rev Oncol Hematol. 2022 Jun;174:103684. doi: 10.1016/j.critrevonc.2022.103684. Epub 2022 Apr 21. Crit Rev Oncol Hematol. 2022. PMID: 35462031 Review.
Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance Against Cancer.
Ciliberto G, Canfora M, Terrenato I, Agnoletto C, Agustoni F, Amoroso L, Baldassarre G, Curigliano G, Delmonte A, De Luca A, Fiorentino M, Gregorc V, Ibrahim T, Lazzari C, Mastronuzzi A, Pronzato P, Santoro A, Scambia G, Tommasi S, Vingiani A, Giacomini P, De Maria R. Ciliberto G, et al. Among authors: agustoni f. J Exp Clin Cancer Res. 2022 Oct 17;41(1):305. doi: 10.1186/s13046-022-02512-0. J Exp Clin Cancer Res. 2022. PMID: 36245005 Free PMC article.
56 results